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The role of haematological traits in risk of
ischaemic stroke and its subtypes
Eric L. Harshfield,1 Matthew C. Sims,2,3 Matthew Traylor,1,4 Willem H. Ouwehand2,5,6,7,8
and Hugh S. Markus1
Thrombosis and platelet activation play a central role in stroke pathogenesis, and antiplatelet and anticoagulant therapies are
central to stroke prevention. However, whether haematological traits contribute equally to all ischaemic stroke subtypes is uncer-
tain. Furthermore, identiﬁcation of associations with new traits may offer novel treatment opportunities. The aim of this research
was to ascertain causal relationships between a wide range of haematological traits and ischaemic stroke and its subtypes. We
obtained summary statistics from 27 published genome-wide association studies of haematological traits involving over 375 000
individuals, and genetic associations with stroke from the MEGASTROKE Consortium (n = 67 000 stroke cases). Using two-
sample Mendelian randomization we analysed the association of genetically elevated levels of 36 blood cell traits (platelets, mature/
immature red cells, and myeloid/lymphoid/compound white cells) and 49 haemostasis traits (including clotting cascade factors and
markers of platelet function) with risk of developing ischaemic (AIS), cardioembolic (CES), large artery (LAS), and small vessel
stroke (SVS). Several factors on the intrinsic clotting pathway were signiﬁcantly associated (P 5 3.85  10–4) with CES and LAS,
but not with SVS (e.g. reduced factor VIII activity with AIS/CES/LAS; raised factor VIII antigen with AIS/CES; and increased
factor XI activity with AIS/CES). On the common pathway, increased gamma (g0) ﬁbrinogen was signiﬁcantly associated with AIS/
CES. Furthermore, elevated plateletcrit was signiﬁcantly associated with AIS/CES, eosinophil percentage of white cells with LAS,
and thrombin-activatable ﬁbrinolysis inhibitor activation peptide antigen with AIS. We also conducted a follow-up analysis in UK
Biobank, which showed that amongst individuals with atrial ﬁbrillation, those with genetically lower levels of factor XI are at
reduced risk of AIS compared to those with normal levels of factor XI. These results implicate components of the intrinsic and
common pathways of the clotting cascade, as well as several other haematological traits, in the pathogenesis of CES and possibly
LAS, but not SVS. The lack of associations with SVS suggests thrombosis may be less important for this stroke subtype. Plateletcrit
and factor XI are potentially tractable new targets for secondary prevention of ischaemic stroke, while factor VIII and g0 ﬁbrinogen
require further population-based studies to ascertain their possible aetiological roles.
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Introduction
Stroke is the second leading cause of death and disability-
adjusted life years worldwide (GBD, 2015 DALYs and
HALE Collaborators, 2015; GBD 2015 Mortality and
Causes of Death Collaborators, 2015). Stroke represents
a syndrome rather than a single disease, and is caused by
a number of distinct pathologies. The majority of strokes
are caused by cerebral ischaemia resulting in infarction, the
most common subtypes of which are large-artery athero-
sclerotic stroke (LAS), cardioembolic stroke (CES), and la-
cunar stroke caused by cerebral small vessel disease (SVS)
(Markus, 2016).
Blood cell traits, clotting factors, and platelet activation
and aggregation pathways are involved in thrombosis and
play a central role in the pathogenesis of stroke (Gregg and
Goldschmidt-Clermont, 2003). Antithrombotic therapy
with both antiplatelet agents and anticoagulants is widely
used in the prevention of stroke (Gregg and Goldschmidt-
Clermont, 2003), and genetic loci associated with risk of
stroke are signiﬁcantly enriched in targets for antithrombo-
tics (Malik et al., 2018). However, the mechanisms by
which disorders associated with these haematological
traits and haemostatic pathways result in ischaemic stroke
is not fully understood. This information is critical for in-
forming the development of new therapeutic targets for
stroke prevention and treatment.
An important question regarding the optimization of sec-
ondary prevention treatment is whether thrombosis is an
important disease mechanism in the major ischaemic stroke
subtypes. Thrombosis and subsequent embolism play a key
role in the pathogenesis of both CES and LAS, although
trial data demonstrate that anticoagulants are more effect-
ive for CES and antiplatelet agents for LAS, suggesting the
underlying thrombotic processes differ (Kapil et al., 2017).
Whether thrombosis plays an important role in SVS is
unknown.
It has been suggested that activation of the coagulation
system is a consequence of stroke itself (Brouns and De
Deyn, 2009), and therefore determining whether altered
coagulation is the cause or consequence of stroke is chal-
lenging. One way of overcoming this limitation is the use of
Mendelian randomization; this technique is increasingly
used to infer causality between exposure and disease
through the use of genetic variants associated with the ex-
posure as instrumental variables (Burgess et al., 2018). The
use of genetic variants, which are randomly allocated
during meiosis, avoids reverse causality and minimizes con-
founding by environmental factors in a manner analogous
to a randomized controlled trial (Burgess et al., 2012).
Recent studies have provided large resources to examine
the causal role of haematological traits in ischaemic stroke
and its subtypes. The recent MEGASTROKE Consortium
provided genome-wide association results from over 67 000
stroke cases and 450000 controls (Malik et al., 2018).
Summary statistics from genome-wide association studies
(GWAS) of numerous haematological traits, which in this
paper refers to both blood cells (e.g. platelet count) and
haemostasis parameters (e.g. factor VIII activity), are also
available (Supplementary Table 1). We used two-sample
Mendelian randomization, which combines published evi-
dence from different data sources to obtain an estimate of
the causal effect (Burgess et al., 2015), to perform a com-
prehensive analysis of whether perturbations in haematolo-
gical traits are implicated in stroke risk, and speciﬁcally
whether certain stroke subtypes cluster with particular
haematological traits.
Materials and methods
Data sources
Genetic associations with haematological traits
We performed analyses using both blood cell traits (derived
from a routine full blood count analysis), and haemostasis
traits relating to the coagulation cascade, ﬁbrinolysis, platelet
function, and cell surface interactions at the vascular wall. An
overview of the relationship between haematological traits and
the various biological pathways involved is shown in Fig. 1.
We obtained genetic association estimates for blood cell
traits from a recent publication on the largest GWAS of
blood cell traits published to date, which involved 36 blood
cell traits measured in 173 480 participants of European an-
cestry from the UK Biobank and INTERVAL studies (Astle
et al., 2016). The traits were classiﬁed under six categories:
(i) platelets; (ii) mature red cells; (ii) immature red cells;
(iv) myeloid white cells; (v) lymphoid white cells; and (vi) com-
pound white cells.
To identify traits relevant to haemostasis we conducted a
systematic review of the literature in PubMed (last updated 2
February 2019) searching for GWAS of all applicable traits.
Details of the search strategy are provided in the
Supplementary material (Appendix 1) and Supplementary
Fig. 1. In circumstances where GWAS results for the same
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trait were available from more than one study, we used sum-
mary statistics from the study with the largest sample size.
The studies for all traits included in the analysis had made
available GWAS summary statistics in the public domain. The
number of participants and genetic instruments available
from each study are summarized in Supplementary Table 1,
and details of the assay methods used by each study are
provided in Supplementary Table 2. All methods with avail-
able summary statistics were included for traits that were
assayed using multiple methods (e.g. factor VIII activity and
factor VIII antigen). We used the Reactome database
(Fabregat et al., 2018) to classify the haemostasis traits ac-
cording to the following expertly curated pathways: (i) ex-
trinsic pathway (tissue factor activation); (ii) intrinsic
pathway (contact activation); (iii) common pathway; (iv) dis-
solution of ﬁbrin clot; (v) platelet adhesion to exposed colla-
gen; (vi) platelet activation, signalling, and aggregation; and
(vii) cell surface interactions at the vascular wall. For traits
that were not easily captured in a single pathway we categor-
ized them based on the pathway that we felt most closely
reﬂected the biology of the trait.
Genetic associations with stroke
We obtained genetic associations with ﬁve stroke outcomes [all
stroke (AS), all ischaemic strokes (AIS), CES, LAS, and SVS]
for two ancestral groupings (European-speciﬁc and transances-
tral meta-analysis) from the MEGASTROKE Consortium,
which included data from 67162 cases and 454450 control
subjects (Malik et al., 2018). Stroke cases were deﬁned based
on WHO criteria (i.e. sudden onset neurological changes of
presumed vascular origin lasting at least 24 h) with stroke
subtypes classiﬁed according to the Trial of Org 10172 in
Acute Stroke Treatment (TOAST) criteria (Adams et al.,
1993). The available summary statistics from
MEGASTROKE included 60 341 cases with any ischaemic
stroke regardless of subtype, of which 9006 were CES, 6688
were LAS, and 11 710 were SVS.
Statistical analyses
Mendelian randomization analysis was used to examine
whether haematological traits have a causal effect on the de-
velopment of ischaemic stroke and/or subtypes of stroke. The
Figure 1 Overview of haematological pathways and targets for stroke treatment and prevention. arrow = agonize; B = basophils;
E = eosinophils; L = lymphocytes; M = monocytes; N = neutrophils; perpendicular symbol = antagonize; R = reticulocytes; scissors = proteolytic
cleavage. Traits significantly associated with one or more stroke subtypes are shown with a red border. Created with BioRender (https://
biorender.com/).
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key assumptions of Mendelian randomization are that the gen-
etic variant(s) used as instrumental variables (i) are associated
with the risk factor; (ii) are not associated with any confoun-
ders of the risk factor–outcome association; and (iii) are inde-
pendently distributed from the outcome conditional on the risk
factor and any confounders (Burgess et al., 2018). Genetic
variants associated with haematological traits were identiﬁed
as above and effect estimates were obtained for each instru-
ment and harmonized with the outcome data, ensuring that the
effect of each single nucleotide polymorphism (SNP) on the
exposure and on the outcome corresponded to the same
allele. We performed linkage disequilibrium clumping to
ensure that the instruments used for each exposure were inde-
pendent by selecting only the SNP with the lowest P-value
amongst all SNPs with a linkage disequilibrium r2 5 0.001.
An estimate of the causal effect was assessed using the inverse-
variance weighted (IVW) method. To provide more robust es-
timates and seek to overcome potential pleiotropy, we per-
formed sensitivity analyses using additional Mendelian
randomization models, namely Mendelian randomization-
Egger regression, the weighted median estimator, and the
simple and weighted mode-based estimators, which facilitated
comparison of the causal estimates under different assumptions
and using different statistical approaches (Burgess et al., 2018).
Analyses were performed separately within the European and
transancestral populations from MEGASTROKE. We applied
a multiple-testing correction for 130 disease pathway compari-
sons (13 pathways  two populations  ﬁve outcomes),
which resulted in a signiﬁcance threshold of P 5 3.85 
10–4.
To assess the potential for latent pleiotropy, we performed
bidirectional Mendelian randomization (also known as reverse
Mendelian randomization) for the signiﬁcantly associated
haematological traits (Zheng et al., 2017). Although we were
not hypothesizing that ischaemic stroke may actually cause
changes in levels of haematological traits, these sensitivity ana-
lyses allowed us to assess whether there were any additional
factors that may be driving the associations. We also per-
formed a phenome-wide association study (PheWAS) using
PhenoScanner (Kamat et al., 2019) to explore whether any
of the SNPs signiﬁcantly associated with both haematological
traits and risk of stroke were also associated with other rele-
vant risk factors for stroke and related diseases. This could
provide evidence of horizontal pleiotropy, an alternative
causal pathway from the SNP to the outcome other than via
the haematological trait under investigation, which would vio-
late the assumptions of Mendelian randomization (Burgess
et al., 2018).
In view of associations we identiﬁed for both factors VIII
and XI with CES, we used longitudinal data from 502 616
participants from the UK Biobank to determine whether a
strongly signiﬁcant genetic variant associated with these traits
altered the risk of future stroke. We estimated hazard ratios
with 95% conﬁdence intervals (CIs) using Cox proportional-
hazards regression models adjusted for age and sex, comparing
the association with ischaemic stroke risk in 3962 individuals
with atrial ﬁbrillation, the most frequent cause of CES (Wolf et
al., 1991; Marini et al., 2005; Gretarsdottir et al., 2008;
Lubitz et al., 2017; Ntaios et al., 2018), to the association in
498 654 control subjects without atrial ﬁbrillation.
Mendelian randomization analyses were performed in R ver-
sion 3.4.4 (R Core Team, 2018) using the ‘TwoSampleMR’
package version 0.4.21 (Hemani et al., 2018), and Cox pro-
portional-hazards regression estimates were obtained using
Stata version 15.1 (StataCorp, 2018). Two-sided P-values
and 95% CIs are presented.
Data availability
The GWAS summary statistics used to perform the analyses
described in this study were obtained from publicly available
published data. All data generated or analysed during this
study are included in this published article and its
Supplementary material.
Results
From our systematic literature review of haematological
traits we obtained published GWAS summary statistics for
36 blood cell traits and 49 haemostasis traits from 27 pub-
lications involving over 375000 individuals (Supplementary
Table 1) (Barbalic et al., 2010; Johnson et al., 2010; Smith
et al., 2010, 2011; Athanasiadis et al., 2011; Lovely et al.,
2011; Pare´ et al., 2011; Edelstein et al., 2012; Huang et al.,
2012, 2014; Oudot-Mellakh et al., 2012; de la Morena-
Barrio et al., 2013; Williams et al., 2013; Ma et al., 2014;
Rocanin-Arjo et al., 2014; de Vries et al., 2015, 2016; Tang
et al., 2015; Astle et al., 2016; van Loon et al., 2016; Dennis
et al., 2017; Pankow et al., 2017; Sennblad et al., 2017;
Kanai et al., 2018; Olson et al., 2018; Stanne et al., 2018;
Sun et al., 2018). Figures 2 and 3 summarize the direction
and magnitude of the association estimates for each haem-
atological trait with each stroke subtype, with stronger as-
sociations indicated by darker colours (red in the positive
direction and blue in the negative direction) and asterisks
to indicate the level of statistical signiﬁcance. Figure 4
shows scatterplots of the associations of each genetic variant
plotted against their association with stroke subtypes for all
traits that had signiﬁcant (P 5 3.85  10–4) or marginally
signiﬁcant (P 5 1  10–3) associations: plateletcrit (PCT),
neutrophil percentage of granulocytes (NEUT%GRAN), eo-
sinophil percentage of white cells (EO%), factor VIII activ-
ity, factor VIII antigen, factor XI activity, gamma (g0)
ﬁbrinogen, protein C (PC) activity, and thrombin-activatable
ﬁbrinolysis inhibitor activation peptide antigen (TAFI-
AP:Ag). Figure 1 highlights signiﬁcant associations from
the Mendelian randomization analysis, provides a represen-
tation of the core components of each of the haematological
pathways, and indicates existing drug targets for stroke pre-
vention and treatment.
Blood cell traits
Amongst the 36 blood cell traits, we observed the strongest
associations for PCT (the volume fraction of blood occu-
pied by platelets) and EO%. We found that genetically
elevated levels of PCT were associated with signiﬁcantly
increased risk of AS, AIS, and CES in both European-
only and transancestral populations (Figs 2, 4A and
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Figure 2 Mendelian randomization results showing causal estimates for association of blood cell traits with stroke and its
subtypes. Mendelian randomization results are grouped by Reactome pathways according to blood cell traits: (i) platelets; (ii) mature red cells;
(iii) immature red cells; (iv) myeloid white cells; (v) lymphoid white cells; and (vi) compound white cells. Refer to Supplementary Table 1 for a
description of each trait. Colours show magnitude and direction of P-value of association for estimate of causal effect using inverse-variance
weighted Mendelian randomization approach. Asterisks indicate the significance of the P-value for the most significant association (either
European or transancestral population): P 5 0.05; P 5 1  10–3; P 5 3.85  10–4.
Haematological traits and risk of ischaemic stroke BRAIN 2019: 0; 1–12 | 5
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z362/5637817 by U
niversity of C
am
bridge user on 25 N
ovem
ber 2019
Figure 3 Mendelian randomization results showing causal estimates for association of haemostasis traits with stroke and its
subtypes. Mendelian randomization results are grouped by Reactome pathways according to haemostasis traits: (i) extrinsic pathway of fibrin
clot formation (tissue factor activation); (ii) intrinsic pathway of fibrin clot formation (contact activation); (iii) common pathway of fibrin clot
formation; (iv) dissolution of fibrin clot; (v) platelet adhesion to exposed collagen; (vi) platelet activation, signalling, and aggregation; and (vii) cell
surface interactions at the vascular wall. Refer to Supplementary Table 1 for a description of each trait. Colours show magnitude and direction of
P-value of association for estimate of causal effect using inverse-variance weighted Mendelian randomization approach. Asterisks also indicate the
significance of the P-value for the most significant association (either European or transancestral population): P5 0.05; P5 1  10–3; P5
3.85  10–4.
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Supplementary Table 3), and increased EO% levels were
signiﬁcantly associated with LAS in both populations
(Figs 2 and 4C). Decreased NEUT%GRAN levels were
also marginally signiﬁcantly associated with LAS in both
populations (Figs 2 and 4B).
Haemostasis traits
We examined three interconnected pathways of the clotting
cascade. On the intrinsic (contact activation) pathway, fac-
tors VIII and XI were signiﬁcantly associated with risk of
stroke (Figs 3, 4D–F and Supplementary Table 4).
Genetically elevated levels of factor VIII antigen and
factor XI activity, and lower levels of factor VIII activity,
were strongly associated with increased risk of AS, AIS,
and CES, predominantly in both European-only and trans-
ancestral populations, and also with LAS in Europeans for
factor VIII activity. Nearly all of the traits on the extrinsic
(tissue factor activation) pathway had suggestive associ-
ations but were not statistically signiﬁcant (Fig. 3).
On the common pathway, genetically lowered levels of g0
ﬁbrinogen (which contains the alternately spliced isoform
of the ﬁbrinogen gamma chain) were signiﬁcantly asso-
ciated with increased risk of AS, AIS, and CES in both
populations (Figs 3 and 4G). Additionally, elevated protein
C activity levels were signiﬁcantly associated with increased
risk of AS in both populations and marginally associated
with AIS in a transancestral population, and there was sug-
gestive evidence that it may also be associated with CES
in both populations (Figs 3 and 4H). Elevated levels of
total ﬁbrinogen also exhibited suggestive evidence of asso-
ciation with LAS, though in the opposite direction to g0
ﬁbrinogen.
The remaining pathways that we examined were related
to dissolution of ﬁbrin clots (ﬁbrinolysis); platelet adhesion
to exposed collagen; platelet activation, signalling, and ag-
gregation; and cell surface interactions at the vascular wall
(Fig. 3). Genetically lowered levels of TAFI-AP:Ag, which is
involved in the dissolution of ﬁbrin clots, were signiﬁcantly
associated with increased risk of AIS in a transancestral
population (Figs 3 and 4I).
We also examined whether genetic variants signiﬁcantly
associated with factors VIII and XI were associated with
risk of future stroke in atrial ﬁbrillation cases and controls
within the UK Biobank. rs710446 in the KNG1 locus was
selected as it was the SNP most strongly associated with
factor XI activity and was also signiﬁcantly associated with
factor VIII activity. The hazard ratios for the association of
rs710446 with ischaemic stroke were 1.44 (95% CI 0.90–
2.31) in individuals with atrial ﬁbrillation and 1.10 (95%
CI 1.02–1.19) in controls without atrial ﬁbrillation (Fig. 5).
However, the absolute magnitude of the reduction in cu-
mulative probability of stroke was much greater in individ-
uals with atrial ﬁbrillation, implying that treatments
designed to reduce the risk of stroke by targeting factor
VIII or factor XI levels are much more likely to be success-
ful in patients with atrial ﬁbrillation.
Bidirectional Mendelian randomiza-
tion and phenome-wide scan
In the reverse Mendelian randomization analyses, we found
that AS and AIS were signiﬁcantly associated with PCT,
EO%, factor VIII activity, factor VIII antigen, factor XI
activity, g0 ﬁbrinogen, and protein C activity. Many of
these associations were found in both the European and
transancestral populations and were conﬁrmed using mul-
tiple Mendelian randomization methods (Supplementary
Table 5). Our PheWAS found that the SNPs signiﬁcantly
associated with haematological traits and risk of stroke
subtypes were also signiﬁcantly associated with other rele-
vant risk factors for stroke and related diseases, such as
body mass index, systolic blood pressure, total cholesterol,
LDL cholesterol, triglycerides, smoking status, coronary
artery disease, and Alzheimer’s disease (Supplementary
Tables 6 and 7).
Discussion
This study provides a comprehensive description of the re-
lationship between haematological traits and the risk of
stroke and its subtypes. It highlights that a number of
haematological traits are causal risk factors for stroke,
but that these associations differ according to stroke sub-
type. The ﬁndings demonstrate that inter-individual genetic
variation affecting several blood cell traits (PCT and
EO%), components of the intrinsic (factors VIII and XI)
and common (g0 ﬁbrinogen and PC activity) pathways of
the clotting cascade, and a ﬁbrinolysis inhibitor (TAFI-
AP:Ag), signiﬁcantly inﬂuence ischaemic stroke risk, par-
ticularly CES and (to a lesser extent) LAS, but not SVS.
Our ﬁndings have a number of clinical implications. First,
they suggest that thrombosis, particularly due to abnorm-
alities in the intrinsic and common pathways of the clotting
cascade, plays an important role in the pathogenesis of
both CES and LAS, but we found no associations with
SVS. Embolism from cardiac pathology causes CES, while
embolism from large-artery stenosis is believed to be the
major pathogenic mechanism underlying LAS (Markus,
2016). Therefore, it is not surprising that genetic variants
that increase thrombosis and thus increase the likelihood of
formation of potential emboli are risk factors for both con-
ditions. The role of thrombosis in SVS is much less certain.
Case-control studies have suggested that platelet activation
and coagulation may be less important for this subtype
(Lavalle´e et al., 2013), while increasing the intensity of
antiplatelet therapy has not been shown to result in any
further reduction of recurrent stroke in patients with SVS
(SPS3 Investigators et al., 2012). Furthermore, a previous
candidate gene study showed the ABO locus, found to be
associated with increased coagulation, was associated with
CES and LAS but not SVS (Williams et al., 2013). Taken
together, these data raise the possibility that SVS is not
driven by perturbations of platelets or the clotting cascade,
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implying that therapies designed to acutely dissolve throm-
bus (thrombolysis) or prevent thrombosis in the longer
term (antithrombotic therapy) may not be effective in
SVS. A further consideration is that small vessel pathology
can cause both ischaemic SVS and deep intracerebral haem-
orrhage (Markus, 2016), meaning that optimizing the type
and intensity of antithrombotic therapy is particularly im-
portant in this patient group. These hypotheses now need
examining in randomized trials in well-phenotyped cohorts
of patients with SVS.
Second, our analysis has identiﬁed new potential targets
for pharmacological therapy and risk reduction of acute
ischaemic stroke, particularly CES. Existing antiplatelet
medication used to treat and prevent ischaemic stroke—
including aspirin, clopidogrel, and dipyridamole—affect
different signalling pathways involved in platelet activation
and aggregation, thereby leading to reduced platelet func-
tion (Fig. 1). Our results suggest that reduction of PCT
should also be considered. PCT is normally tightly con-
trolled by the hormone thrombopoietin (TPO). TPO mi-
metics are drugs used for the treatment of immune
thrombocytopenia, characterized by accelerated platelet
clearance from the circulation and low platelet count and
PCT (Kuter, 2009; Tang et al., 2017). Therefore, a possible
avenue for pharmacological research in acute ischaemic
stroke would be the converse, i.e. antagonism of TPO or
its haematopoietic stem cell receptor, MPL, in order to
reduce PCT levels.
The intrinsic pathway of the clotting cascade is stimu-
lated in vivo by methods including contact with nega-
tively-charged polyphosphates released from activated
platelets (Long et al., 2016). It culminates in the coupling
together of factor IX with its cofactor factor VIII to acti-
vate factor X. The only currently available anticoagulant
used in stroke that acts on the intrinsic pathway is war-
farin, which diminishes hepatic synthesis of factor IX as
well as prothrombin (factor II) and factor X in the
common pathway and factor VII in the extrinsic pathway.
Disadvantages of warfarin include the inconvenience of
regular blood tests for monitoring and annualized risk of
major bleeding of 3% (Hylek et al., 2014). This makes
our ﬁnding that higher factor XI activity is signiﬁcantly
associated with an increased risk of AIS, and particularly
CES, especially pertinent, as agents that reduce factor XI
synthesis in the liver (Zhang et al., 2010) and inhibit the
action of factor XI’s activated form (factor XIa) (Lin et al.,
2006; Tucker et al., 2009; Donkor et al., 2017; Woodruff
et al., 2017) have already been developed. Phase I and II
Figure 4 Genetic associations with haematological traits and stroke subtypes with significant causal estimates. The associations
of each genetic variant associated with haematological traits with significant (P 5 3.85  10–4) or marginally significant (P 5 1  10–3) causal
estimates are plotted against their association with selected stroke subtypes. Circles represent the associated change in levels of the trait and
corresponding increased risk of stroke for each variant. The horizontal and vertical lines through each circle represent the corresponding 95% CIs
for the genetic associations. Associations were oriented to the effect allele of each trait. Coloured lines show the slope (causal estimate) of the
trait on stroke obtained using a variety of different Mendelian randomization (MR) approaches. Trait/outcome/population: (A) PCT/CES/
European; (B) NEUT%GRAN/LAS/transancestral; (C) EO%/LAS/transancestral; (D) factor VIII activity/CES/European; (E) factor VIII antigen/CES/
European; (F) factor XI activity/AIS/European; (G) g0 fibrinogen/CES/transancestral; (H) protein C activity/CES/transancestral population; and (I)
TAFI-AP:Ag/AIS/transancestral. See Supplementary Table 1 for a description of each trait.
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clinical trials of antisense oligonucleotides in several hun-
dred individuals have shown that they reduce factor XI
levels, have a major bleeding risk of only 0–1% (Liu
et al., 2011), and are superior in reducing radiologically
detected asymptomatic deep vein thrombosis (Bu¨ller et al.,
2015). Our study extends the ﬁnding of a recent publica-
tion on the association of factor XI levels with AIS and
CES in nearly four times as many stroke cases and 14
times as many control subjects (Gill et al., 2018). Taken
together with the early phase clinical trial data, there is
now strong support for the need for randomized clinical
trials of the use of factor XI inhibitors versus standard-
of-care in ischaemic stroke, such as the international sec-
ondary stroke prevention trial using factor XIa inhibitor
BMS-986177 (United States National Institutes of Health,
2019).
Our results indicate that factor VIII may also be a drug-
gable target to consider for the prevention of both CES and
LAS. To validate our ﬁndings, we demonstrated that the
genetic variant most strongly associated with factor VIII
activity and also associated with factor XI activity pre-
dicted risk of future stroke in patients with atrial ﬁbrilla-
tion in the UK Biobank. Notably, the effect estimate was
stronger in individuals with atrial ﬁbrillation compared to
those without atrial ﬁbrillation, albeit the association in
atrial ﬁbrillation cases was not statistically signiﬁcant,
which is likely due to insufﬁcient power. This suggests
that drugs designed to inhibit factor XI activity (Bane
and Gailani, 2014) or increase factor VIII activity might
be effective at reducing the risk of ischaemic stroke in pa-
tients with atrial ﬁbrillation, although studies with larger
numbers of atrial ﬁbrillation cases and randomized con-
trolled trials would be needed to validate this ﬁnding.
Additionally, the opposing direction of effect of factor
VIII on stroke risk when measured by different assays
means that further clariﬁcation of this ﬁnding in other
population-based studies is required.
Through enzymatic cleavage of factor X to its activated
form, factor Xa is the start of the common pathway that
results in the generation of a ﬁbrin clot. Existing anticoagu-
lants used for secondary stroke prevention that affect this
pathway include direct factor Xa and thrombin (factor IIa)
inhibitors apixaban, rivaroxaban, and dabigatran (Fig. 1).
However, our ﬁnding that increased levels of g0 ﬁbrinogen
reduce the risk of AIS and CES would suggest that other
distinct molecular pathways could potentially modify is-
chaemic stroke risk. g0 ﬁbrinogen results from the alternate
splicing of one of the three genes (FGG), that is translated
into ﬁbrinogen and normally comprises 7% of circulating
ﬁbrinogen (Lovely et al., 2011), and has distinct
Figure 5 Role of genetic variants associated with haematological traits in mediating association of atrial fibrillation with risk of
ischaemic stroke. Cumulative probability of ischaemic stroke in individuals with normal and genetically lowered levels of factor XI (FXI) activity
(based on rs710446 alleles in KNG1 locus) in UK Biobank participants (A) without atrial fibrillation and (B) with atrial fibrillation.
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biochemical properties (Gersh et al., 2009). After an acute
ischaemic stroke, increased g0 ﬁbrinogen levels have been
associated with higher scores for short-term disability (van
den Herik et al., 2011); however, the raised g0 ﬁbrinogen
may reﬂect an acute phase response to stroke and it is dif-
ﬁcult to ascribe causation (Farrell, 2012). Indeed, given that
g0 ﬁbrinogen demonstrates defective platelet aggregation
compared with ﬁbrinogen (Farrell et al., 1992), there is a
biologically plausible mechanism by which g0 ﬁbrinogen is
protective against ischaemic stroke that warrants further
examination in prospective longitudinal studies.
One of the strengths of our analysis is that we show that
several haematological traits are still strongly signiﬁcant
despite correcting for multiple statistical tests across all
traits and outcomes. We only corrected for the number of
disease–pathway comparisons analysed rather than the
total number of unique traits, as this would have been
too conservative due to correlations between many highly
related traits. Some traits, such as factors X and XIII, were
only measured in small studies (e.g. 2000 individuals or
less), so they were penalized after the correction for mul-
tiple testing was applied and limited our power to detect
associations with stroke. Likewise, there were approxi-
mately six times more cases available for all stroke than
for subtypes of ischaemic stroke, so our power to detect
statistically signiﬁcant associations was also more limited
for the ischaemic stroke subtypes (CES, LAS, and SVS).
Additionally, many of the traits exhibited suggestive evi-
dence (P 5 0.05) that genetically altered levels of these
traits could lead to increased risk of one or more stroke
subtypes, though they did not reach the threshold for stat-
istical signiﬁcance after correction for multiple testing and
therefore could be spurious ﬁndings. Further examination
of more detailed associations between haematological traits
and stroke subtypes than was accomplished in this analysis
will only be feasible when larger samples sizes of well-phe-
notyped stroke cases become available.
Our study also has a few limitations. Our systematic
review of GWAS of haematological studies was limited to
studies listed in PubMed published in English, so there may
be other studies that we missed. Additionally, two-sample
Mendelian randomization should ideally be applied using
non-overlapping datasets for obtaining genetic associations
with the exposure and the outcome to reduce weak instru-
ment bias (Burgess et al., 2018). However, overlap between
participants was unavoidable for some traits because the
largest available published GWAS of those traits were mea-
sured in studies that were also included as part of the
MEGASTROKE Consortium, such as the CHARGE
Consortium, which comprised 10.7% of the total
European stroke cases, and the BioBank Japan Project,
which comprised 24.2% of the total non-European stroke
cases (Malik et al., 2018). Summary statistics from
CHARGE and BioBank Japan were used to obtain genetic
associations with the exposure for seven of the 85 traits.
Moreover, there was signiﬁcant heterogeneity amongst the
different types of haemostasis traits that may limit their
direct comparability. Several traits such as factor VIII anti-
gen and protein C activity were only associated with a
single independent SNP, so the causal estimates for these
traits are less robust than for other traits that were asso-
ciated with a large number of independent SNPs.
Furthermore, the small number of participants included in
some of the studies (e.g. 352 for antithrombin and 116 for
PFA-100ColA) means that their genetic associations are less
reliable than for the traits that were measured in tens or
hundreds of thousands of individuals (e.g. 164 339 for
PCT), which in turn limits the reliability of the causal in-
ferences for these traits. Finally, the signiﬁcant associations
detected in the reverse Mendelian randomization analyses
and PheWAS suggest that there is a possibility of horizontal
pleiotropy if the outcomes were affected through other
traits or pathways to those under investigation, so these
ﬁndings should be interpreted with caution. Nevertheless,
despite these limitations, we have applied a rigorous ana-
lysis approach to ensure our reported ﬁndings are as robust
as possible.
In conclusion, we provide the ﬁrst comprehensive ana-
lysis of the role of genetically elevated blood cell and
haemostasis traits on risk of stroke. Of the 85 different
traits that we analysed, PCT, EO%, factor VIII, factor
XI, g0 ﬁbrinogen, protein C activity, and TAFI-AP:Ag
have been identiﬁed as novel risk factors for ischaemic
stroke, and we provide further support for the role of
raised factor XI in its aetiology. Haematological traits
also differentially associate with various stroke subtypes,
suggesting the role of thrombosis may differ for different
stroke subtypes. Methods for reducing PCT and factor XI
levels should now be further examined in experimental and
clinical research settings as potential new targets for sec-
ondary stroke prevention. We also demonstrate that this
approach may identify potential drug targets for novel
antithrombotic drugs.
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